Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

3 Recruiting

6 Completed trials

7 Sponsors

12 Countries

Phase III

Phase II

Phase IV

Phase III: 5 Phase II/III: 1 Phase II: 4 Phase III/IV: 1 Phase IV: 2

Indications tested

Respiratory syncytial virus infection 3 Respiratory syncytial virus bronchitis 2 Pneumonia respiratory syncytial viral 2 Respiratory syncytial virus bronchiolitis 2 Allogenic stem cell transplantation 1 Polyarthritis 1 Systemic lupus erythematosus 1 Lung transplant 1 Rheumatoid arthritis 1 Giant cell arteritis 1 Polymyalgia rheumatica 1

Sponsors using this IMP

GlaxoSmithKline Biologicals 7 Centre hospitalier universitaire de Liege 1 Hospices Civils De Lyon 1 Karolinska Institutet 1 Medical University Of Vienna 1 Nordsjaellands Hospital 1 Region Skane 1

All trials

13 total

Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on… Pending

2024-518191-31-00 Phase IV 1 country Region Skane
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients Pending

2024-519163-18-00 Phase IV 1 country Nordsjaellands Hospital
RISE Pending

2024-520141-23-01 Phase III 1 country Karolinska Institutet
Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant r… Pending

2025-524374-42-00 Phase II 1 country Hospices Civils De Lyon
A study evaluating persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccinatio… Recruiting

2024-519730-23-00 Phase II 3 countries GlaxoSmithKline Biologicals
A Phase II randomized trial of RSV vaccination in allogeneic hematopoietic stem cell transplant recipients (RSV-Allo study) Recruiting

2024-513290-53-00 Phase II/III 1 country Centre hospitalier universitaire de Liege
A phase-2b controlled study to evaluate the humoral and cellular immune response and safety following one and two doses of an adjuvanted RSV… Recruiting

2024-513187-25-00 Phase II 1 country Medical University Of Vienna
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Phase III 7 countries GlaxoSmithKline Biologicals
Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 yea… Ended

2024-512291-34-00 Phase III 2 countries GlaxoSmithKline Biologicals
A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine… Ended

2023-509455-13-00 Phase III/IV 3 countries GlaxoSmithKline Biologicals
A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin… Ended

2023-510196-59-00 Phase III 3 countries GlaxoSmithKline Biologicals
A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased … Ended

2023-510190-34-00 Phase III 1 country GlaxoSmithKline Biologicals
A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney trans… Ended

2023-503951-81-00 Phase II 3 countries GlaxoSmithKline Biologicals

Showing 1–13 of 13 trials

← All drugs A–Z